The Daily Biotech Pulse: Moderna’s Vaccine Produces Durable Response Against Variants, FDA Approves Jazz’s Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 12)
Hoth Therapeutics Highlights North Carolina State University Findings Of HT-KIT
Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today highlights recent findings from North Carolina State University, that its new treatment for mast
22 Stocks Moving in Wednesday’s Pre-Market Session
Gainers
CohBar, Inc. (NASDAQ: CWBR) shares rose 78.3% to $2.30 in pre-market trading after the company reported results from the Phase 1a/1b study of CB4211 under development for NASH and obesity met its primary endpoint. The company also released Q2 results.
Paper Out Of NC State University Earlier, Published In Molecular Therapy ”Frameshifting’ Therapy for Mast Cell Cancers Reduces Size, Spread’ Highlights Hoth Therapeutics Technology
https://news.ncsu.edu/2021/08/frameshifting-therapy-mast-cell-cancers-reduces-size-spread/
Hoth Therapeutics Reports Initiation Of Preclinical Study Of HT-ALZ For Alzheimer’s Disease
Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, announced today that it has initiated its preclinical study utilizing Hoth's HT-ALZ in an animal model.
The goal
Hoth Therapeutics To Present Data On Preclinical Results For Its HT-KIT For mRNA Frame-Shifting On Jun. 3 at 1 p.m. EDT
Shareholder Presentation Today to Further Highlight Results
HT- KIT Reduces KIT expression and induces apoptosis of neoplastic human mast cells
Inhibits tumor growth in humanized xenograft mast cell neoplasia